Communications BiologyThe development of cisplatin resistance often results in a grim prognosis in advanced or recurrent bladder cancer. However, effective treatment strategies for cisplatin resistance have not been well established.
Yuwen Gong +15 more
doaj +1 more source
Molecular mechanisms of cisplatin resistance in ovarian cancer
Genes and DiseasesOvarian cancer is one of the most common malignant tumors of the female reproductive system. The majority of patients with advanced ovarian cancer are mainly treated with cisplatin-based chemotherapy.
Chenying Jiang +7 more
doaj +1 more source
Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 Noncoding RNA in Ovarian A2780 Cells [PDF]
, 2018 Cisplatin resistance is one of the main limitations in the treatment of ovarian cancer, which is partly mediated by long noncoding RNAs (lncRNAs). H19 is a lncRNA involving in cisplatin resistance in cancers. Valproic acid (VPA) is a commonly used drug
Amini-Farsani, Zeinab. +6 more
core
Cisplatin resistance in urothelial carcinoma [PDF]
, 2018 Bladder cancer is the 9th most common tumour worldwide with Urothelial Carcinoma (UC) being the most frequent type of the disease. Cisplatin-based chemotherapy is the standard of care in advanced and metastatic UC. However, its therapeutic efficacy is limited by chemoresistance. Cisplatin-resistant UC cell lines were generated to investigate underlying
openaire +2 more sources
Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. [PDF]
, 2012 MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC ...
Bourguignon, LYW +4 more
core
npj Precision OncologyChemotherapy such as cisplatin is widely used to treat ovarian cancer either before or after surgical debulking. However, cancer relapse due to chemotherapy resistance is a major challenge in the treatment of ovarian cancer.
Anjali Geethadevi +13 more
doaj +1 more source
SH3RF2 contributes to cisplatin resistance in ovarian cancer cells by promoting RBPMS degradation
Communications BiologyPlatinum-based chemotherapy remains one of the major choices for treatment of ovarian cancer (OC). However, primary or acquired drug resistance severely impairs their efficiency, thereby causing chemotherapy failure and poor prognosis.
Ting-Ting Gong +17 more
doaj +1 more source
Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. [PDF]
, 2017 Predictive biomarkers have the potential to facilitate cancer precision medicine by guiding the optimal choice of therapies for patients. However, clinicians are faced with an enormous volume of often-contradictory evidence regarding the therapeutic ...
Beckman, Robert A. +8 more
core +1 more source
Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells [PDF]
, 2017 et al,, Ghasemi, Reza
core +2 more sources
GATOR1 complex controls cisplatin sensitivity
Cell Death and DiseaseCisplatin administration is the primary chemotherapy approach for many epithelial cancers. However, resistance to this drug poses a significant challenge to effective treatment.
Zhenrui Pan +4 more
doaj +1 more source